glp 1 compounders FDA Intensifies Crackdown on GLP-1 Compounding FDA Moves to Close a
Description
Fras JP, Auerbach P, Bajaj HS et al (2021) Efficacy and safety of once-weekly semaglutide 20 mg versus 10 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

However, Zynquista was never marketed in Europe

The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020

Thats why microdosing gets so much attention

B.LiB.et al (2014)
